A genetic predisposition to having lower insulin production and less healthy fat distribution are major causes of early-onset type 2 diabetes in British Asian people.
Adjuvant Osimertinib as a Standard Therapy for EGFR-Positive NSCLC
Treatment with osimertinib (Tagrisso) after surgery significantly reduced the risk of death in adults with completely resected EGFR-positive stage IB, II, or IIIA non-small cell
July 7, 2023